EDITORIAL BY PATRICK ALEXANDRE   Founder & CEO   The core expertise of a specialty pharmaceutical laboratory, like that of any industrial company, lies in its ability to manage cycles. For nearly three years, the industrial scale-up cycle has been a major focus for CROSSJECT. In this edition’s Focus, Didier Morin, Industrial Director, and Xavier Perin, Head of Development and Industrialization, provide insight into the drivers behind our steady progress and explain how our industrial impulse is being built step by step.   At the same time, another critical cycle is at the very heart of our priorities as we begin 2026 : the validation process of our first drug, ZEPIZURE®. We have now entered its final stage, the regulatory phase.     EDITORIAL BY PATRICK ALEXANDRE   Founder & CEO   The core expertise of a specialty pharmaceutical laboratory, like that of any industrial company, lies in its ability to manage cycles. For nearly three years, the industrial scale-up cycle has been a major focus for CROSSJECT. In this edition’s Focus, Didier Morin, Industrial Director, and Xavier Perin, Head of Development and Industrialization, provide insight into the drivers behind our steady progress and explain how our industrial impulse is being built step by step.   At the same time, another critical cycle is at the very heart of our priorities as we begin 2026 : the validation process of our first drug, ZEPIZURE®. We have now entered its final stage, the regulatory phase.       Joint interview with Didier Morin, Industrial Director, and Xavier Perin, Head of Development and Industrialization. Joint interview with Didier Morin, Industrial Director, and Xavier Perin, Head of Development and Industrialization.     What specific challenges does the industrial manufacturing of ZENEO® present?   Before addressing the challenges, it is important to highlight a key industrial advantage of ZENEO®. Our needle-free auto-injector is a common platform across all medications developed by CROSSJECT; it is the injector’s configuration that differentiates each indication.   That said, the manufacturing of ZENEO® must meet a dual requirement. In addition to the constraints inherent to medical devices, production must comply with the very stringent rules governing the handling of energetic materials classified as powders and explosives.   What specific challenges does the industrial manufacturing of ZENEO® present?   Before addressing the challenges, it is important to highlight a key industrial advantage of ZENEO®. Our needle-free auto-injector is a common platform across all medications developed by CROSSJECT; it is the injector’s configuration that differentiates each indication.   That said, the manufacturing of ZENEO® must meet a dual requirement. In addition to the constraints inherent to medical devices, production must comply with the very stringent rules governing the handling of energetic materials classified as powders and explosives.                 CROSSJECT at the Heart of Key European Investor Meetings   At the end of the year, CROSSJECT multiplied strategic engagements, meeting with more than 150 European investors, primarily small-cap fund managers and family offices.   From Copenhagen to Monaco, via Munich, Frankfurt and Geneva, these meetings provided an opportunity to share the Group’s vision and progress.     CROSSJECT at the American Epilepsy Society 2025   Tony Tipton, COO & Head of CROSSJECT US, represented the group at the 2025 annual meeting of the American Epilepsy Society, a key event for the international epilepsy community.   The CROSSJECT team engaged with clinicians, researchers, and partners committed to improving seizure management.     ZENEO® at the Élysée and in Versailles   As a laureate of the Grande Exposition du Fabriqué en France, the needle-free auto-injector ZENEO® was presented on November 15 and 16 at the Élysée Palace.   The group then took part in the Forum Innovation Défense in Versailles, highlighting an emergency drug delivery solution designed to meet the needs of both civilian and military interventions.   CROSSJECT at the Heart of Key European Investor Meetings   At the end of the year, CROSSJECT multiplied strategic engagements, meeting with more than 150 European investors, primarily small-cap fund managers and family offices.   From Copenhagen to Monaco, via Munich, Frankfurt and Geneva, these meetings provided an opportunity to share the Group’s vision and progress.     CROSSJECT at the American Epilepsy Society 2025   Tony Tipton, COO & Head of CROSSJECT US, represented the group at the 2025 annual meeting of the American Epilepsy Society, a key event for the international epilepsy community.   The CROSSJECT team engaged with clinicians, researchers, and partners committed to improving seizure management.     ZENEO® at the Élysée and in Versailles   As a laureate of the Grande Exposition du Fabriqué en France, the needle-free auto-injector ZENEO® was presented on November 15 and 16 at the Élysée Palace.   The group then took part in the Forum Innovation Défense in Versailles, highlighting an emergency drug delivery solution designed to meet the needs of both civilian and military interventions.   www.crossject.com www.crossject.com     You received this email because you subscribed to this newsletter.